- Home
- ANGO vs SABS Comparison
ANGO vs SABS Comparison
Compare ANGO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | SABS |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 344.8M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANGO | SABS |
|---|---|---|
| Price | $15.30 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.00 | $10.75 |
| AVG Volume (30 Days) | ★ 306.1K | 260.5K |
| Earning Date | 04-02-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $9.39 | $1.85 |
| 52 Week High | $16.29 | $5.15 |
Technical Indicators
Market Signals| Indicator | ANGO | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 45.42 |
| Support Level | $14.85 | $3.39 |
| Resistance Level | $16.23 | $4.02 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 25.00 | 44.79 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.